title: [Advancement of biotherapy for malignant lymphoma].
abstract: In the past 30 years, the incidence of lymphoma was increasing. Although it is very sensitive to chemotherapy, and many new cytotoxic drugs and chemotherapy regimens have emerged, the 5-year survival rate of lymphome patients is only 40%-50%. With the development of immunology, the importance of biotherapy evoked more and more attention, and have became an important composition in the treatment of lymphoma. The most widely used biotherapy methods are listed as follows: monoclonal antibody, radioimmunotherapy, adoptive immunotherapy, active immunotherapy, gene therapy targeting Bcl-2, and targeted chemotherapy. Using these biotherapy methods in combination with other treatment methods reasonably will help to improve the short-term and long-term results of lymphoma.
authors.affiliation: Skate Key Laboratory of Oncology in Southern China, Cancer Center, Sun Yat-sen University, Guangzhou, Guangdong, P. R. China. wenqijiang@yahoo.com
authors.forename: Wen-Qi
authors.initials: WQ
authors.lastname: Jiang
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D058846:Antibodies, Monoclonal, Murine-Derived; D018951:Antigens, CD20 / Q000276:immunology; D000970:Antineoplastic Agents / Q000627:therapeutic use; D015316:Genetic Therapy; D006801:Humans; D007167:Immunotherapy / Q000379:methods*; D008223:Lymphoma / Q000401:mortality / Q000628:therapy*; D016499:Radioimmunotherapy; D000069283:Rituximab; D015996:Survival Rate
chemical_list: D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D018951:Antigens, CD20; D000970:Antineoplastic Agents; D000069283:Rituximab; C422802:ibritumomab tiuxetan